Literature DB >> 20332705

Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

P Agretti1, G De Marco, D Sansone, C Betterle, G Coco, A Dimida, E Ferrarini, A Pinchera, P Vitti, M Tonacchera.   

Abstract

BACKGROUND: Vitiligo is an acquired depigmenting disorder characterized by the loss of melanocytes from the epidermis with the development of white patches in various distribution. The pathogenesis of vitiligo is still unknown, but the association with autoimmune disorders and organ specific autoantibodies, supports the hypothesis of an autoimmune pathogenesis. AIM: The aim of the present study was to investigate if autoantibodies present in sera of patients affected by vitiligo may be able to interfere with the activity of the αMSH on the melanocortin 1 receptor (MC1R). MATERIALS/ SUBJECTS AND METHODS: IgG from the sera of 41 patients with vitiligo associated or not with thyroid autoimmune diseases or other autoimmune pathologies were incubated with HBL20 cells (human malignant melanocytes expressing the MC1R) in the presence of a sub-maximal dose of αMSH. A normal IgG range was determined by using IgG extracted from 30 control sera of normal subjects.
RESULTS: None of the IgG from vitiligo patients was able to inhibit αMSH-stimulated cAMP production in HBL20 cells.
CONCLUSIONS: Autoantibodies against MC1R are rare or absent in sera of vitiligo patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332705     DOI: 10.1007/BF03350342

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  47 in total

Review 1.  Serum antibodies in vitiligo patients.

Authors:  J C Bystryn
Journal:  Clin Dermatol       Date:  1989 Apr-Jun       Impact factor: 3.541

2.  Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Br J Dermatol       Date:  1998-11       Impact factor: 9.302

Review 3.  Vitiligo.

Authors:  S O Kovacs
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

4.  Correlation between vitiligo antibodies and extent of depigmentation in vitiligo.

Authors:  G K Naughton; D Reggiardo; J C Bystryn
Journal:  J Am Acad Dermatol       Date:  1986-11       Impact factor: 11.527

Review 5.  Vitiligo.

Authors:  R A Schwartz; C K Janniger
Journal:  Cutis       Date:  1997-11

6.  Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells.

Authors:  W Siegrist; F Solca; S Stutz; L Giuffrè; S Carrel; J Girard; A N Eberle
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

7.  In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo.

Authors:  A Gilhar; B Zelickson; Y Ulman; A Etzioni
Journal:  J Invest Dermatol       Date:  1995-11       Impact factor: 8.551

8.  Vitiligo autoantibodies are effective against melanoma.

Authors:  P Fishman; E Azizi; Y Shoenfeld; B Sredni; G Yecheskel; S Ferrone; R Zigelman; S Chaitchik; S Floro; M Djaldetti
Journal:  Cancer       Date:  1993-10-15       Impact factor: 6.860

9.  The expression of functional MSH receptors on cultured human melanocytes.

Authors:  P D Donatien; G Hunt; C Pieron; J Lunec; A Taïeb; A J Thody
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

10.  The role of tyrosinase in autoimmune vitiligo.

Authors:  Y H Song; E Connor; Y Li; B Zorovich; P Balducci; N Maclaren
Journal:  Lancet       Date:  1994-10-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.